文献速递肾小球疾病

抗体指导治疗在磷脂酶A2受体相关膜性肾病中的应用

Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy.
PubMed 文献 · Kidney Int Rep · 2022-12-13

本研究评估抗体指导方案治疗磷脂酶A2受体相关膜性肾病的疗效:65例高危患者接受环磷酰胺1.5 mg/kg/d联合激素,每8周为一周期,第8、16、24周检测抗PLA2R抗体,阴性即停环磷酰胺并快速减撤泼尼松;24周抗体持续阳性者换用吗替麦考酚酯,复发者重复治疗。结果显示免疫学缓解率8周71%、16周86%、24周88%、3年94%,总部分缓解率92%,抗体指导治疗与标准6个月疗程同样有效且环磷酰胺累积剂量更低。

要点

  • 抗体指导方案根据第8、16、24周抗PLA2R抗体结果决定环磷酰胺停药与泼尼松减量。
  • 免疫学缓解率8周71%、16周86%、24周88%、3年94%,总部分缓解率92%。
  • 抗体指导治疗与标准6个月疗程同样有效,环磷酰胺累积剂量更低(11.1 vs 18.9 g)。

核心结论

  • 抗体指导治疗有效,可实现个体化治疗,许多患者仅8周环磷酰胺为基础的治疗即获缓解。

研究设计与样本

  • 纳入65例(男48例、女17例)磷脂酶A2受体相关膜性肾病且进展高风险患者,年龄61±12岁。
  • 给予环磷酰胺1.5 mg/kg/d联合激素,以8周为一周期;第8、16、24周用间接免疫荧光法检测抗PLA2R抗体。
  • 抗体检测阴性即停用环磷酰胺并快速减撤泼尼松;第24周抗体持续阳性者将环磷酰胺换为吗替麦考酚酯;复发者重复治疗。

主要发现

  • 免疫学缓解率8周为71%、16周为86%、24周为88%、3年为94%。
  • 27例(42%)仅治疗8周后即维持临床缓解;16例因免疫学或临床复发需要第二疗程。
  • 随访37(26-58)个月,总部分缓解率92%,1例进展至终末期肾病。
  • 抗体指导治疗与标准6个月疗程同样有效,环磷酰胺累积剂量更低(11.1 [8.0-18.5] vs 18.9 [14.2-23.6]克)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A 6-month course of cyclophosphamide (CP) and steroids is effective in primary membranous nephropathy (MN), but unappealing because of long-term side effects. We evaluated efficacy of an "antibody-guided" treatment schedule. METHODS: Patients with phospholipase A2 receptor (PLA2R)-related MN and high risk of progression were treated with CP 1.5 mg/kg/d and steroids in cycles of 8 weeks. Anti-PLA2R antibodies were measured by indirect immunofluorescence (IIFT) at 8, 16, and 24 weeks, and a negative test resulted in withdrawal of CP, and rapid tapering of prednisone. In patients with persistent anti-PLA2R antibodies at 24 weeks, CP was switched to mycophenolate mofetil. Treatment was repeated in patients with a relapse. RESULTS: Our analysis included 65 patients (48 males, 17 females), age 61 ± 12 years, estimated glomerular filtration rate (eGFR) 46 ml/min per 1.73 m2 (35-68), urine protein-to-creatinine ratio 7.7 grams/10 mmol creatinine (5.4-11.1) and serum albumin 20 g/l (16-26). Immunologic remission rate was 71% after 8 weeks, 86% after 16 weeks, 88% after 24 weeks, and 94% after 3 years. Twenty-seven patients (42%) had persistent clinical remission after only 8 weeks of therapy. Sixteen patients needed a second course of therapy because of immunologic or clinical relapse. Follow-up was 37 (26-58) months. Overall partial remission rate was 92%. One patient developed end-stage kidney disease. Antibody-guided therapy (ABG) was as effective as the standard 6-month course, whereas providing a lower cumulative dose of CP (11.1 [8.0-18.5] vs. 18.9 [14.2-23.6] grams). CONCLUSION: ABG is effective, and allows individualized therapy, with many patients responding to 8 weeks of CP-based therapy.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Vink CH, Logt AV, van der Molen RG, et al. Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy. Kidney Int Rep. 2022. PMID: 36938074. doi:10.1016/j.ekir.2022.12.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。